Biocon launches two FDA-approved interchangeable denosumab biosimilars in the US, targeting osteoporosis and bone metastasis in a $5B market.
Your 99.9% germ-free habits may be hurting long-term immunity. Here is what the hygiene hypothesis says about how these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results